|
|
Upfront Briefing
In Washington, the Senate health committee chair floated a reform framework touching FDA approvals, real-world evidence, and clinical holds — the kind of “rule-talk” that can reprice regulatory risk across biotech.
Meanwhile, reality checks arrived in stereo: big pharma kept writing meaningful checks (Novartis ↔ Unnatural Products), and private capital showed up in size (Korsana’s $175M Seed/A) — while public financing stayed open but selective (Compass $150M; Eupraxia $55M).
Tape Action
| Instrument |
Last close |
1D % |
YTD % |
| S&P 500 |
6,881.31 |
+0.6% |
+0.5% |
| Nasdaq 100 |
24,898.87 |
+0.8% |
(1.4%) |
| Russell 2000 |
2,658.61 |
+0.5% |
+7.1% |
| Healthcare (XLV) |
157.67 |
+0.2% |
+1.9% |
| Biotech (XBI) |
125.62 |
+0.8% |
+3.0% |
| Nasdaq Biotech (NBI) |
5,996.81 |
+0.4% |
+5.1% |
| Clinical Trials (BBC) |
41.00 |
+1.3% |
+5.1% |
|
-
Risk-on tape: U.S. indices moved higher, led by megacap tech/AI (Nvidia/Meta headlines helped set the tone).
-
Biotech participated (XBI +0.8%, NBI +0.4%), while small caps remain the YTD winner (+7.1%) as the market keeps rotating into higher-beta exposures.
-
Market data: U.S. close Wed 18-Feb-2026.
The Big 3
|
1
|
Senate HELP chair floats FDA reform framework
|
-
Senate HELP Chair Bill Cassidy outlined a reform framework touching FDA approval pathways, use of real-world evidence, clinical holds, and U.S. competitiveness.
-
Why it matters:
If this direction turns into policy, it could reprice regulatory risk by changing what “adequate evidence” looks like (e.g., RWE acceptance, pivotal-trial expectations) and by altering the economics of development (hold dynamics, timelines, and capital intensity) — with knock-on effects for trial design, partnering leverage, and cost of capital across the sector.
-
Source:
Endpoints
|
|
2
|
Novartis inks big-ticket oncology license with Unnatural Products
|
-
Novartis licensed oncology programs from Unnatural Products in a deal reported as $100M upfront and up to $1.7B total consideration (milestones/royalties).
-
Why it matters:
Large pharma is still writing meaningful checks for differentiated oncology shots — and the upfront + headline total matters for how the market prices “platform-to-product” translation risk, especially for earlier programs where financing windows are selective.
-
Source:
PR
|
|
3
|
Korsana launches with $175M Seed/A
|
-
Korsana launched with a reported $175M Seed/Series A financing.
Syndicate: Seed led by Fairmount & Venrock; Series A co-led by Wellington & TCGX; joined by J.P. Morgan LS Private Capital, Janus Henderson, Sanofi Ventures, Foresite (and others).
-
Why it matters:
A $175M start is a reminder that private capital is still available at scale for “newco-quality” stories — even as public windows stay selective. It also sets a high bar for what gets funded: team, asset quality, and a crisp path to value inflection.
-
Source:
Fierce
|
Everything Else that broke
-
Pharma resists Trump’s push to codify pricing deals. —
Endpoints
-
NIH’s Jay Bhattacharya named acting CDC chief. —
BioSpace
-
BioVersys Phase 2a TB trial results published in NEJM. —
NEJM
(PR:
PR)
-
NEJM publishes MARINA trial results for myotonic dystrophy type 1. —
NEJM
(PR:
PR)
-
Clinical AI startup Kintsugi shuts down. —
Endpoints
-
ctDNA surrogate endpoints will require standards and specificity. —
BioCentury
-
Hansa Biopharma: FDA accepts BLA for imlifidase. —
PR
-
Zealand Pharma reports full-year 2025 financial results. —
PR
Deal Flow
|
BioBucks 2026 Deal Trackers • Updated weekly
⬇️
|
M&A / BD&L
-
Novartis licenses oncology programs from Unnatural Products — reported $100M upfront, up to $1.7B total. —
PR
-
Eli Lilly licenses clazakizumab rights from CSL — reported $100M upfront, up to $1.14B total. —
BioPharma Dive
-
Sensei acquires Faeth alongside a $200M PIPE. —
SEC deck
VC / Private Financings
-
Korsana Biosciences launches with $175M Seed/A. Syndicate:
Seed led by Fairmount & Venrock; Series A co-led by Wellington & TCGX; joined by J.P. Morgan LS Private Capital, Janus Henderson, Sanofi Ventures, Foresite (and others). —
Fierce
IPOs / Follow-Ons
-
Compass Pathways prices $150M public offering. —
PR
-
Eupraxia Pharmaceuticals prices $55M public offering. —
PR
Academic Corner
- Hematopoietic Stem-Cell Gene Therapy for Cystinosis. — NEJM
- One Pivotal Trial, the New Default Option for FDA Approval — Ending the Two-Trial Dogma. — NEJM
- Gene Therapy for Nephropathic Cystinosis. — NEJM
- FDA relaxes oversight for wellness devices. — Nature Biotech
|
|
That’s it for today — file the prospectus, then file your inbox. See you tomorrow. BioBucks Team
|
|
|
